tANCHOR-based Immunization

Skip Purification.

When speed and precision matter in antibody development, traditional immunization strategies often fall short. Expressing and purifying antigens for vaccination in model organisms like mice is not only labor-intensive but also slows the production of urgently needed monoclonal antibodies (mAbs).

Enter tANCHOR-based immunization: A breakthrough in quick antigen delivery.

This innovative display technology allows direct presentation of antigens on the surface of human cells, eliminating the need for protein purification before immunization. Using tANCHOR system, researchers can rapidly generate quick immune responses in mice—cutting down critical time in therapeutic antibody development.

In our studies, tANCHOR successfully induced strong antibody responses against a variety of proteins, including:

• The receptor-binding domain (RBD) of SARS-CoV-2

• The extracellular loop of canine CD20

Why tANCHOR for immunization?

• No purification required – just clone, transfect, and immunize

• Rapid, reliable antibody generation against custom antigens

• Versatile platform for infectious disease, oncology, and beyond

Whether you're chasing the next therapeutic mAb or exploring novel immunogens, tANCHOR accelerates your path from antigen to antibody—with minimal hands-on time and maximum flexibility.

Revolutionizing immunization

Monoclonal Antibodies

Tailored production of monoclonal antibodies for challenging antigens, such as GPCRs, ROR1, P2X7, Kv10.1, CXCR4, GPRC5D, or CLDN18.2, with tumor-specific extracellular loops (ECLs).

Polyclonal Antibodies

Rapid production of polyclonal antibodies targeting difficult antigens, without the need for antigen purification. This approach offers a quicker and cost-effective solution for generating antibodies against complex or hard-to-isolate targets.

Accelerate Antibody Discovery

Reference

Bernauer H., Schlör A., Maier J., Bannert N., Hanack K., Ivanusic D. tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2. Oxford Academic Press Biology Methods and Protocols, 2023 Dec. bpad030.

Ivanusic D., Madela K., Burghard H., Holland G., Laue M., Bannert N. tANCHOR: a novel mammalian cell surface peptide display system. Biotechniques. 2021 Jan;70(1):21-28.

Straight to the surface. Straight to immune response.